Gilead says its twice-yearly shot cut HIV infections by 96% in trialThe data sets the stage for likely approval of Gilead's lenacapavir for HIV prevention.[Collection]

The data sets the stage for likely approval of Gilead's lenacapavir for HIV prevention.https://www.cnbc.com/2024/09/12/gilead-lenacapavir-cut-hiv-infections-by-96percent-in-trial.html